https://t.co/DjbbpqOiRf
Great to see our new updated guideline out — British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024
Lots of imp new guidance ….
We find that overall provision of high-quality information is low, with large variation in quantity and quality across websites providing BRCA information. There is a need for improved accessible and high-quality online BRCA information provision
The news today is deeply shocking and saddening for so many of us. Michael Mosley worked closely with the BBC Studios Science Unit across a broadcasting career spanning four decades. His passing will leave a huge hole for so many of us who had the privilege of working with Michael and for the millions of people who loved watching and listening to him. From Trust Me I’m a Dr to Just One Thing, The One Show, Horizon and so many more titles that have educated and entertained in equal measure. His contribution to audiences around the world is unparalleled, as one of the very finest science communicators, as a brilliant programme maker and a unique presenter. For all of us in the Science Unit, we have lost the kindest of colleagues, an inspirational creative mind and a friend.
https://t.co/ToDE3H5TSH Great to see our paper on cost effectiveness of panel germline and somatic testing in ovarian cancer patients out in JNCCN. Panel germline is cost-effective compared to BRCA testing alone and should replace BRCA testing alone.
Delighted to give the Frederick P Li lecture on Precision Prevention in women’s cancers at Dana Farber. Thank you Judy Garber and team for a memorable event.
My trusty live sized knitted gut was looking a little worse for wear, so am grateful to Lesley Daly from the Swaffham’s Women’s Institute for knitting me a new one!!
https://t.co/jDGZZj21uX Delighted to see the new NICE Guideline NG241 out on - Ovarian cancer: identifying and managing familial and genetic risk. Huge effort over 2.5 years. Big Thank You to the entire Committee and the NICE team as well as stakeholders contributing to this
https://t.co/jDGZZj21uX Delighted to see this new NICE Guideline NG241 ‘Ovarian cancer: identifying and managing familial and genetic risk’ published today. A huge effort >2.5 years. Grateful to the entire committee, NICE team & all stakeholders who contributed to this.
New NICE Guideline. Fulfils a huge unmet need. Provides new guidance on issues linked to genetic/pathogenic variant & ovarian cancer risk assessment, genetic counselling/testing, surveillance, surgical prevention, preventive medication, information & support, service organisation
👇👇👇This is excellent news for people with Lynch syndrome in England - and a world first. Huge congratulations to everyone involved @kevinjmonahan @PWMJohnson #bowelcancer#lynchsyndrome
2️⃣ Is there any change to duration of use for endometrial protection?
No, the Mirena licensed duration of use for endometrial protection as part of HRT is 4 years, however FSRH guidance supports use of any 52mg LNG-IUD for endometrial protection as part of HRT for 5 years.
The FSRH has issued a statement on Mirena® 52mg LNG-IUD which is now licensed for 8 years for contraception, so what does this mean for existing users and users of other 52mg LNG-IUDs? 🤔
This week is #CancerPreventionActionWeek
We in the Women's Precision Prevention team are committed to cancer prevention research!
One small thing you can do is make sure to move your body every day for this years theme #MakeYourMove
My talk on @TEDTalks has passed 500k views in under 3 weeks.
I'm just getting my head around that.
It seems that when we talk about dying with clarity & truth, the 'taboo' falls away. People really want to know more.
I hope it consoles many more people.
https://t.co/AkBjWGm2nm